279 related articles for article (PubMed ID: 37435085)
1. Antigen presentation by clonally diverse CXCR5+ B cells to CD4 and CD8 T cells is associated with durable response to immune checkpoint inhibitors.
Ding L; Sun L; Bu MT; Zhang Y; Scott LN; Prins RM; Su MA; Lechner MG; Hugo W
Front Immunol; 2023; 14():1176994. PubMed ID: 37435085
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
3. Influence of Tumor Immune Infiltration on Immune Checkpoint Inhibitor Therapeutic Efficacy: A Computational Retrospective Study.
Liu R; Yang F; Yin JY; Liu YZ; Zhang W; Zhou HH
Front Immunol; 2021; 12():685370. PubMed ID: 34220837
[TBL] [Abstract][Full Text] [Related]
4. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
5. Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment.
Kim H; Park S; Han KY; Lee N; Kim H; Jung HA; Sun JM; Ahn JS; Ahn MJ; Lee SH; Park WY
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36787939
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: A multiplex immunohistochemistry-based single-cell analysis.
Isomoto K; Haratani K; Tsujikawa T; Makutani Y; Kawakami H; Takeda M; Yonesaka K; Tanaka K; Iwasa T; Hayashi H; Ito A; Nishio K; Nakagawa K
Lung Cancer; 2022 Dec; 174():71-82. PubMed ID: 36347190
[TBL] [Abstract][Full Text] [Related]
7. Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma.
Park S; Cha H; Kim HS; Lee B; Kim S; Kim TM; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Park WY; Lee SH
Cancer Med; 2023 Mar; 12(6):7639-7650. PubMed ID: 36453453
[TBL] [Abstract][Full Text] [Related]
8. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
10. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Hsieh CH; Jian CZ; Lin LI; Low GS; Ou PY; Hsu C; Ou DL
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053457
[TBL] [Abstract][Full Text] [Related]
11. Decreased survival in patients treated by chemotherapy after targeted therapy compared to immunotherapy in metastatic melanoma.
Mangin MA; Boespflug A; Maucort Boulch D; Vacheron CH; Carpentier I; Thomas L; Dalle S
Cancer Med; 2021 May; 10(10):3155-3164. PubMed ID: 33932099
[TBL] [Abstract][Full Text] [Related]
12. Functional Th1-oriented T follicular helper cells that infiltrate human breast cancer promote effective adaptive immunity.
Noël G; Fontsa ML; Garaud S; De Silva P; de Wind A; Van den Eynden GG; Salgado R; Boisson A; Locy H; Thomas N; Solinas C; Migliori E; Naveaux C; Duvillier H; Lucas S; Craciun L; Thielemans K; Larsimont D; Willard-Gallo K
J Clin Invest; 2021 Oct; 131(19):. PubMed ID: 34411002
[TBL] [Abstract][Full Text] [Related]
13. CXCL13-mediated recruitment of intrahepatic CXCR5
Li Y; Tang L; Guo L; Chen C; Gu S; Zhou Y; Ye G; Li X; Wang W; Liao X; Wang Y; Peng X; Liu G; Zhang X; Sun J; Peng J; Hou J
J Hepatol; 2020 Mar; 72(3):420-430. PubMed ID: 31610223
[TBL] [Abstract][Full Text] [Related]
14. B Cells Are Required to Generate Optimal Anti-Melanoma Immunity in Response to Checkpoint Blockade.
Singh S; Roszik J; Saini N; Singh VK; Bavisi K; Wang Z; Vien LT; Yang Z; Kundu S; Davis RE; Bover L; Diab A; Neelapu SS; Overwijk WW; Rai K; Singh M
Front Immunol; 2022; 13():794684. PubMed ID: 35720386
[TBL] [Abstract][Full Text] [Related]
15. The microbial metabolite desaminotyrosine enhances T-cell priming and cancer immunotherapy with immune checkpoint inhibitors.
Joachim L; Göttert S; Sax A; Steiger K; Neuhaus K; Heinrich P; Fan K; Orberg ET; Kleigrewe K; Ruland J; Bassermann F; Herr W; Posch C; Heidegger S; Poeck H
EBioMedicine; 2023 Nov; 97():104834. PubMed ID: 37865045
[TBL] [Abstract][Full Text] [Related]
16. The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF.
Harrer C; Otto F; Pilz G; Haschke-Becher E; Trinka E; Hitzl W; Wipfler P; Harrer A
Fluids Barriers CNS; 2021 Aug; 18(1):40. PubMed ID: 34446066
[TBL] [Abstract][Full Text] [Related]
17. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
18. Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Bochem J; Zelba H; Spreuer J; Amaral T; Wagner NB; Gaissler A; Pop OT; Thiel K; Yurttas C; Soffel D; Forchhammer S; Sinnberg T; Niessner H; Meier F; Terheyden P; Königsrainer A; Garbe C; Flatz L; Pawelec G; Eigentler TK; Löffler MW; Weide B; Wistuba-Hamprecht K
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34933966
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibition promotes immune infiltration in ovarian cancer and synergizes with PD-1 blockade in a B cell-dependent manner.
Zhang QF; Li J; Jiang K; Wang R; Ge JL; Yang H; Liu SJ; Jia LT; Wang L; Chen BL
Theranostics; 2020; 10(23):10619-10633. PubMed ID: 32929370
[TBL] [Abstract][Full Text] [Related]
20. Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy.
Rose AAN; Armstrong SM; Hogg D; Butler MO; Saibil SD; Arteaga DP; Pimentel Muniz T; Kelly D; Ghazarian D; King I; Kamil ZS; Ross K; Spreafico A
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33483342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
